High-Definition transcranial Direct Current Stimulation (HD-tDCS) is a transformative technology for targeting cortical and deep brain structures with weak DC currents. Unlike any other neuromodulation technique, HD-tDCS is non-invasive, targeted, and can leverage the therapeutic potential, convenience, safety, and cost-advantages of tDCS. Soterix medical is the exclusive manufacturer and provider of HD-tDCS technology.
Exclusively from Soterix Medical, HD-tDCS is the only clinically validated system for non-invasive and targeted neuromodulation.
Do not be compromised by un-tested copycat devices. Soterix Medical’s unmatched team of biomedical engineers and scientists is ready to support you to deploy the right HD-tDCS system for your application.
High-Definition transcranial Direct Current Stimulation (HD-tDCS) was invented at The City University of New York with the introduction of the 4x1 HD-tDCS montage (Datta 2009). The 4x1 HD-tDCS montage categorically transformed the possibilities with non-invasive neuromodulation but allowing precise targeting of cortical structures. How focal is 4x1 HD-tDCS? The region of current flow is circumscribed by the area of the 4x ring, such that decreasing ring radius increased focality. Soterix Medical Neurotargeting software makes HD montage design fast and easy. But the innovation did not stop there. Scientists went on to demonstrate that 4x1 HD-tDCS allow for unifocal stimulation, meaning the polarity of the center 1x electrode will determine the direction of neuromodulation under the ring (Villamar 2013). This is in contrast to conventional tDCS where the need for one anode and one cathode always produces bidirectional modulation (even when an extra-cephalic electrode is used). 4x1 HD-tDCS thus provides the ability not only to select a cortical brain region to target, but to modulate the excitability of that brain region with a designed polarity without having to consider return counter-electrode flow.
There is only one electrode design that has been engineered for HD-tDCS, validated in extensive clinical testing, and used in clinical trials. The High Definition electrode was designed at The City University Of New York (Minhas 2010) and been proven safe and well tolerated in multi-center clinical trials (Borckardt 2012, Villamar 2013, Kuo 2013). It is critical investigators do not attempt multi-electrode stimulation with non-validated “off-brand” devices under the assumption these approaches have any relevance to Soterix Medical HD-tDCS technology or clinical validated approaches. Use of off-brand electrodes and devices compromise research integrity, patient safety, and interferes with the rational development of HD-tDCS by the research community.
A critical question given the targeting of 4x1 HD-tDCS is “when is focality desired?” There is no simple answer to this question but is it important to recognize that most conventional tDCS approach produce current flow through >50% of the brain including deep brain structures and that with conventional tDCS inter-individual anatomical difference means the location of peak brain electric field will vary widely. Therefore, by guaranteed peak brain electric field at the target and restricting brain current flow to a limited region, 4x1 HD-tDCS confers some theoretical clinical benefits. In ongoing clinical trials, 4x1 HD-tDCS has consistently produced effects size comparable or exceeding alternative neuromodulation protocols, including in control of experiment and clinical pain (Borckardt 2012, Villamar 2013). More striking, in a direct comparison with conventional tDCS, Nitsche and Paulus demonstrated that 4x1 HD-tDCS produce change in brain excitability that significantly exceed both the magnitude and duration of conventional tDCS (Kuo 2013).